America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How have the preliminary results from the AOH1996 trials compared to traditional chemotherapy options in terms of efficacy and side effects?
**Interview with Dr. Linda Malkas on New Cancer Drug AOH1996**
*Interviewer:* Thank you for joining us today, Dr. Malkas. You’ve been making headlines with the development of a new cancer drug called AOH1996. Can you start by explaining what makes this drug unique?
*Dr. Malkas:* Absolutely, thank you for having me. AOH1996 is groundbreaking because it utilizes a targeted chemotherapy approach. This drug specifically targets a mutated variant of the protein PCNA, which plays a critical role in DNA replication and tumor growth. By focusing on this cancer-specific variant, we aim to selectively kill cancer cells while sparing normal cells.
*Interviewer:* That sounds promising! How does AOH1996 actually work in the body?
*Dr. Malkas:* Think of PCNA as a major airline terminal hub. Cancer cells have a unique mutation in PCNA, which allows us to design our drug, AOH1996, like a blizzard that disrupts the flow of planes—only in this case, those planes carry cancer cells. By disrupting the cell’s normal reproductive cycle, AOH1996 can effectively eliminate the proliferating cancer cells.
*Interviewer:* You’ve conducted significant research using AOH1996. What can you tell us about the results so far?
*Dr. Malkas:* In our studies published in *Cell Chemical Biology*, we tested AOH1996 on over 70 different cancer cell lines, including those from breast, prostate, and lung cancers. The results were very encouraging; we observed that AOH1996 selectively killed the cancer cells while showing minimal effects on normal cells.
*Interviewer:* That sounds like a major advancement in cancer treatment. What’s the next step for this research?
*Dr. Malkas:* The next critical step is to transition into clinical trials with human participants. We’re currently preparing for that phase, which will help us determine the drug’s efficacy and safety in a clinical setting.
*Interviewer:* what does this mean for patients who are currently battling cancer?
*Dr. Malkas:* If our clinical trials are successful, AOH1996 could offer a new, less toxic treatment option for patients with various forms of cancer. We believe that targeted therapies like this one will pave the way for more personalized and effective cancer treatments.
*Interviewer:* Thank you, Dr. Malkas, for sharing your insights on this exciting development in cancer therapy.
*Dr. Malkas:* Thank you for having me! It’s an exciting time in cancer research, and I look forward to seeing the impact of our work on patients’ lives.
